MedTrace Logo

A Study of Danavorexton in Anesthetized Adults

NCT05025397 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-05-10

No results posted yet for this study

Summary

The aims of the study are:

* to assess the safety profile of danavorexton when it is administered with anesthetics.
* to learn what effect danavorexton has on anesthetized adults.

On Day 1, participants will receive a single intravenous (IV) infusion of danavorexton or a placebo after participants have been anesthetized for about 40 minutes. Clinic doctors will arrange a follow-up visit by phone or video on Day 7.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Danavorexton

Danavorexton intravenous infusion.

DRUG

Danavorexton Placebo

Danavorexton placebo-matching intravenous infusion.

DRUG

Propofol

Propofol intravenous bolus.

DRUG

Sevoflurane

Sevoflurane inhalation.

DRUG

Propofol

Propofol intravenous infusion.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-28
Primary Completion
2022-03-08
Completion
2022-03-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05025397 on ClinicalTrials.gov